What the Moderna-NIH COVID vaccine patent fight means for research.

Ledford, Heidi

Ledford, Heidi.

Nature ; 600(7888): 200-201, 2021 12.

Article in English | MEDLINE | ID: covidwho-1545592

Subject(s)

2019-nCoV Vaccine mRNA-1273; Dissent and Disputes; Drug Industry; Inventors/legislation & jurisprudence; National Institutes of Health (U.S.); Patents as Topic/legislation & jurisprudence; Research Personnel/legislation & jurisprudence; 2019-nCoV Vaccine mRNA-1273/economics; 2019-nCoV Vaccine mRNA-1273/genetics; 2019-nCoV Vaccine mRNA-1273/supply & distribution; Drug Industry/economics; Drug Industry/legislation & jurisprudence; Humans; Inventors/economics; National Institutes of Health (U.S.)/economics; National Institutes of Health (U.S.)/legislation & jurisprudence; Ownership/economics; Ownership/legislation & jurisprudence; Public-Private Sector Partnerships/economics; Public-Private Sector Partnerships/legislation & jurisprudence; Research Personnel/economics; SARS-CoV-2/genetics; United States

Keywords

Intellectual-property rights; SARS-CoV-2; Vaccines

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Patents as Topic / Research Personnel / Dissent and Disputes / Drug Industry / Inventors / 2019-nCoV Vaccine mRNA-1273 / National Institutes of Health (U.S.) Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Humans Country/Region as subject: North America Language: English Journal: Nature Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google